| scholarly article | Q13442814 |
| P2093 | author name string | Alain H Litwin | |
| Matthew J Akiyama | |||
| Philippe J Zamor | |||
| Brianna L Norton | |||
| P2860 | cites work | Outcomes of treatment for hepatitis C virus infection by primary care providers | Q24601722 |
| Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews | Q24630669 | ||
| Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis | Q26822903 | ||
| A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice | Q27692040 | ||
| Best strategies for global HCV eradication | Q27693824 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir | Q28084266 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. | Q30209037 | ||
| Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs. | Q33684172 | ||
| Successful integration of hepatitis C evaluation and treatment services with methadone maintenance | Q33858467 | ||
| Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics | Q34073122 | ||
| Hepatitis C management by addiction medicine physicians: results from a national survey | Q34090853 | ||
| Formal Patient Education Improves Patient Knowledge of Hepatitis C in Vulnerable Populations | Q34435133 | ||
| Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting | Q34539238 | ||
| Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study | Q34725432 | ||
| Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection | Q34777639 | ||
| Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? | Q34795087 | ||
| Eradication of hepatitis C infection: the importance of targeting people who inject drugs. | Q34984077 | ||
| Liver transplant and hepatitis C in methadone maintenance therapy: a case report | Q35633613 | ||
| Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment | Q35634124 | ||
| Changes in the prevalence of injection drug use among adolescents and young adults in large U.S. metropolitan areas | Q35821718 | ||
| Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone | Q35960681 | ||
| Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy | Q36086391 | ||
| Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection | Q36184653 | ||
| Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment | Q36296243 | ||
| Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study | Q36296251 | ||
| Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program | Q36421892 | ||
| Pharmacokinetic interaction between telaprevir and methadone | Q36785929 | ||
| Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance | Q37002923 | ||
| Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy | Q37042425 | ||
| Indicators of buprenorphine and methadone use and abuse: what do we know? | Q37045326 | ||
| Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users | Q37196683 | ||
| Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program | Q37216987 | ||
| Limited uptake of hepatitis C treatment among injection drug users | Q37238205 | ||
| Hepatitis C treatment for injection drug users: a review of the available evidence | Q37546106 | ||
| Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals | Q37601315 | ||
| Hepatitis C virus infection in USA: an estimate of true prevalence | Q37899936 | ||
| Hepatitis C virus reinfection following treatment among people who use drugs | Q38123941 | ||
| Drug-drug interactions in the treatment of HCV among people who inject drugs | Q38123943 | ||
| Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. | Q38123944 | ||
| Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. | Q38123945 | ||
| Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. | Q38123948 | ||
| Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection | Q38446524 | ||
| Direct-acting antiviral agents for HCV infection affecting people who inject drugs | Q38613271 | ||
| Drug interactions between buprenorphine, methadone and hepatitis C therapeutics | Q38824198 | ||
| Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication | Q39664785 | ||
| Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. | Q39820916 | ||
| Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals | Q39910287 | ||
| Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. | Q40476713 | ||
| Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials | Q40565822 | ||
| Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials | Q40565832 | ||
| Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States | Q40786866 | ||
| Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine | Q41358146 | ||
| Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy | Q41493705 | ||
| Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir | Q41506667 | ||
| Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. | Q42243136 | ||
| Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial | Q42280277 | ||
| Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial | Q42280281 | ||
| Recommendations for the management of hepatitis C virus infection among people who inject drugs. | Q42280296 | ||
| Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy | Q42685176 | ||
| A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance | Q42986145 | ||
| Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection | Q42989154 | ||
| Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance | Q42994848 | ||
| High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin | Q42996009 | ||
| A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. | Q43035164 | ||
| Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users | Q43039432 | ||
| Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study | Q43570051 | ||
| Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy | Q44337654 | ||
| Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients | Q44341935 | ||
| Access to care of patients with chronic hepatitis C virus infection in a university hospital: Is opioid dependence a limiting condition? | Q44342833 | ||
| The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. | Q44979610 | ||
| Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services | Q45205749 | ||
| Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. | Q45366817 | ||
| Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities | Q45497659 | ||
| Adherence to hepatitis C treatment in recovering heroin users maintained on methadone | Q46126021 | ||
| Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study | Q48850680 | ||
| Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. | Q50573750 | ||
| Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. | Q51831518 | ||
| Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. | Q53118691 | ||
| Treatment of chronic hepatitis C in active drug users. | Q53479050 | ||
| Previous Intravenous Substance Use and Outcome of Liver Transplantation in Patients With Chronic Hepatitis C Infection | Q57081686 | ||
| Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility | Q57701087 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | best practice | Q830382 |
| opioid | Q427523 | ||
| infectious disease | Q18123741 | ||
| chronic hepatitis C | Q55779873 | ||
| P304 | page(s) | 347-370 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | Infectious Disease Clinics of North America | Q15754797 |
| P1476 | title | Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice | |
| P478 | volume | 32 |
Search more.